Definium releases second successful anxiety trial results
1 Sep 14 7:01 AM · 10d ago · 1 article · 1 source · development 1 of 3
In a 245-patient trial, a single 100-microgram dose of DT120 reduced anxiety scores by 9.8 points after 12 weeks, compared with 4.7 points for placebo. Benefits appeared as early as day two and sustained through week 12. The 50-microgram dose also showed efficacy but less than the 100-microgram dose.
“A single 100-microgram dose of DT120, a fast-dissolving tablet of lysergide, or LSD, reduced scores on an anxiety scale by 9.8 points after 12 weeks, compared with a 4.7-point decline for placebo.”
Definium TherapeuticsDefinium Therapeutics Company developing DT120Robert Barrow CEO, Definium TherapeuticsGavin Clark-Gartner Analyst, Evercore ISI
The whole story articles the bright band is this development · numbered dots are the others · click one to jump
What was reported 2 claims about this development
-
first by STAT, 9d ago · also Yahoo Finance
2 more headlines
- Definium's LSD-based anxiety, depression drug scores another trial win reuters.com · 9d ago
- Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching Yahoo Finance · 3d ago
-
first by Medscape, 10d ago
All 3 developments of Definium's LSD therapy clears second late-stage anxiety… →
NewswiresGoogle NewsReddit